CellRapeutics™ Chimeric Autoantibody Receptor (CAAR) T Cell Development Service

In the realm of autoimmune disorders, the emergence of innovative immunotherapy approaches has sparked a new wave of hope for patients worldwide. Leveraged by the power of engineered T cells to target autoreactive B cells responsible for autoimmune disorders, Creative Biolabs is committed to providing the innovative CellRapeutics™ Chimeric Autoantibody Receptor (CAAR) T cells development service to advance therapeutics development.

CellRapeutics™ Chimeric Autoantibody Receptor (CAAR) T Cell Development Services at Creative Biolabs

The innovative CAAR technology allows for the precise engineering of T cells to recognize and eliminate autoantibody-producing B cells, offering a personalized approach to treat conditions like lupus nephritis, myasthenia gravis, and pemphigus vulgaris. In the development of Chimeric Autoantibody Receptor (CAAR) T cells, Creative Biolabs is committed to providing specialized solutions aimed at targeting autoreactive B cells associated with various autoimmune disorders. Our featured solutions include the following items, but not limited to:

• Variable Design and Construction of CAART
• Isolation and Culture of Primary Cells
• Immuno-oncology Model Assays
• Cutting-edge CAAR Solutions for Specificity and Cytotoxicity Assessment In Vitro and In Vivo

Popular Target for Chimeric Autoantibody Receptor (CAAR) T Cells Development

• Desmoglein 3
• MBP
• La/SSB
• MuSK
• FVIII

Scientific Backing

Current research, as highlighted by Ellebrecht et al., has demonstrated the successful application of CAAR T cells against autoreactive B cells targeting desmoglein 3 in pemphigus vulgaris. The engineered CAAR T cells exhibited effective and target-specific cytotoxicity, showcasing the potential of this approach in autoimmune disease therapy. Similarly, studies have shown the development of CAAR T cells against autoreactive B cells producing antibodies in systemic lupus erythematosus, myasthenia gravis, and hemophilia.

Fig.1 In vivo efficacy of Dsg3 CAAR-Ts against anti-Dsg3 target cells.¹

What we can offer

• Innovative CAAR design and construction approaches;
• Customized CAAR development services tailored to specific autoimmune disorders;
• Cutting-edge CAAR solutions for enhanced cytotoxicity and target-specific elimination of autoreactive B cells both in vitro and in vivo;
• Expert team of biologists.

Partner with Creative Biolabs to Accelerate CAAR T Cells Development

While the CellRapeutics™ CAAR T cells Development service holds great promise in the field of autoimmune disease treatment, it is essential to acknowledge certain limitations. One key limitation is the diversity of autoantigens involved in autoimmune diseases, which can vary among patients and evolve. This variability poses a challenge in designing CAAR T cells that can effectively target all relevant autoantigens simultaneously.

Furthermore, CAAR T cells may be ineffective against plasma cells, as they downregulate surface immunoglobulins during differentiation, leading to treatment resistance. To address this limitation, innovative approaches for selective plasma cell depletion, such as utilizing protein conjugates, may enhance the efficacy of CAAR T cell therapy. We are also trying to overcome these difficulties through various development platforms. Contact Creative Biolabs today to learn more about our CellRapeutics™ CAAR T cells development service.

Reference

1. Ellebrecht, Christoph T., et al. "Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease." Science 353.6295 (2016): 179-184.